Glycine transporter (GlyT) neurons are inhibitory circuit components in which synaptic glycine signaling is defined by SLC6A5/GlyT2 and SLC6A9/GlyT1. These transporters shape fast inhibitory neurotransmission in spinal cord and brainstem networks and also regulate NMDA receptor co-agonist availability in forebrain microdomains.[1][2]
Because glycinergic pathways support motor patterning, sensorimotor gating, respiratory rhythm, and nociceptive processing, transporter dysfunction can propagate through systems commonly affected in neurodegenerative disease, especially disorders with gait, autonomic, or bulbar involvement.[3][4]
| Property | Value |
|---|---|
| Category | Inhibitory neuron-associated transporter systems |
| Core genes | SLC6A5, SLC6A9 |
| Principal regions | Spinal cord, medulla, pontine and reticular networks |
| Primary function | Glycine reuptake, synaptic termination, inhibitory gain control |
| Disease links | Hyperekplexia, pain circuitry dysfunction, motor network instability |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Allen Brain Cell Atlas | Search | Glycine Transporter (GlyT) Neurons |
| Cell Ontology (CL) | Search | Check classification |
| Human Cell Atlas | Search | Check expression data |
| CellxGene Census | Search | Check cell census |
GlyT2 is concentrated in glycinergic axon terminals and is essential for sustaining vesicular glycine loading and quantal inhibitory transmission. Loss-of-function states reduce inhibitory reserve and produce exaggerated startle and hyperexcitability phenotypes.[1:1][5]
GlyT1 is enriched in glia and selected neurons and modulates extracellular glycine near NMDA receptors. This creates a mechanistic link between inhibitory glycine handling and excitatory glutamatergic plasticity relevant to cognition and neurodegeneration.[2:1][6]
Effective GlyT1/GlyT2 balance maintains spinal and brainstem inhibitory tone, limiting pathological synchronization in descending motor and autonomic pathways. Disruption can amplify motor rigidity, pain sensitization, and brainstem dysautonomia phenotypes seen in advanced degeneration.[3:1][4:1]
Human genetics established SLC6A5 mutations as a major cause of hyperekplexia, confirming that glycine transporter integrity is required for stable inhibitory gating in pontomedullary startle circuits.[1:2][5:1]
In dorsal horn networks, glycine transport sets inhibitory efficacy that gates nociceptive transmission. Pharmacologic GlyT2 modulation can alter analgesic response without fully suppressing physiological reflexes when selectivity is optimized.[7][8]
Forebrain GlyT1 manipulation changes glycine microenvironment at NMDA receptors and influences cognition-related phenotypes, which is relevant when cognitive decline intersects with inhibitory dysfunction in Alzheimer's disease and dementia with Lewy bodies.[6:1][9]
Degenerative disorders affecting medullary and spinal inhibitory circuits can be worsened by impaired glycinergic buffering. This is especially relevant to syndromes with falls, bulbar dysfunction, and respiratory instability, including Parkinson's disease, multiple system atrophy, and amyotrophic lateral sclerosis.[3:2][4:2]
When glycinergic inhibition weakens, excitatory burden rises in vulnerable motor circuits. Combined with mitochondrial stress and neuroinflammation, this may accelerate neuronal injury in disease contexts already close to excitotoxic threshold.[7:1]
GlyT inhibitors and allosteric modulators remain active translational targets for pain, startle syndromes, and network stabilization strategies. The challenge is to increase therapeutic inhibition while preserving critical reflex and respiratory functions.[8:1][9:1]
The study of Glycine Transporter (Glyt) Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Eulenburg V, Armsen W, Betz H, Gomeza J. The glycine transporter GlyT2 in mouse spinal cord: expression, function, and targeting to glycinergic synapses. European Journal of Neuroscience. 2005. ↩︎ ↩︎ ↩︎
Eulenburg V, Gomeza J. Neurotransmitter transporters expressed in glial cells as regulators of synapse function. Brain Research Reviews. 2010. ↩︎ ↩︎
Zeilhofer HU, Wildner H, Yévenes GE. Fast synaptic inhibition in spinal sensory processing and pain control. Physiological Reviews. 2012. ↩︎ ↩︎ ↩︎
Schorge S, Elmslie FV, Colquhoun D, et al. A common domain for hyperekplexia mutations in the human glycine receptor alpha1 subunit. Nature Neuroscience. 1998. ↩︎ ↩︎ ↩︎
Rees MI, Harvey K, Pearce BR, et al. Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease. Nature Genetics. 2006. ↩︎ ↩︎
Yee BK, Balic E, Singer P, et al. Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. The Journal of Neuroscience. 2006. ↩︎ ↩︎
Morita K, Motoyama N, Kitayama T, et al. Activity of novel lipid glycine transporter inhibitors on synaptic signalling in the dorsal horn of the spinal cord. British Journal of Pharmacology. 2018. ↩︎ ↩︎
Mostyn SN, Wilson KA, Bendas G, et al. A reversible allosteric inhibitor of GlyT2 alleviates neuropathic pain without on-target side effects. bioRxiv. 2025. ↩︎ ↩︎
Mierzejewski P, Korkosz A, Rog J, et al. Supplementation of antipsychotic treatment with sarcosine, a GlyT1 inhibitor, changes glutamatergic spectroscopy parameters in stable schizophrenia. Neuroscience Letters. 2015. ↩︎ ↩︎